Excellent comment, I do think it’s an inhibiting factor. However, the concept of translational medicine, FHIR as an open healthcare data standard, and moves from the government are moving the dial toward change.
I think a bigger issue is UX in healthcare settings for this type of technology and knowledge. A lot of physicians don’t understand precision medicine, molecular profiling, or clinical trials (especially those studies with molecularly based inclusion/exclusion criteria). I think designing for patients and physicians to make actionable, and insightful systems with this data will be a bigger challenge going forward.